Apotex Pharmachem Inc.

Apotex Inc.

Mohammed Abdul Raheem

Yajun Zhao

Zhi-Xian Wang

Stuart P Green

Minh T N Nguyen

Gamini Weeratunga

Allan W Rey

Fabio E S Souza

Bhaskar Reddy Guntoori

Alexander J Stirk

Siva Ramarao Kakani

Carlos Zetina-Rocha

Alfredo Paul Ceccarelli

Jenny L Gerster

Eckardt C G Wolf

Mohamed Ibrahim Zaki

Eduardo Gustavo Cammisa

Fatemeh Mohammadpourmir

The present invention provides novel crystalline forms of zuclomiphene citrate. Specific crystalline forms provided by the present invention include zuclomiphene citrate Forms APO-I, APO-II, APO-III, and APO-IV. Also provided are pharmaceutical compositions including the zuclomiphene citrate crystalline forms, processes for the preparation thereof and the use of these forms in the treatment of a disorder selected from the group including osteoporosis, bone fractures, loss of bone mineral density (BMD) and hot flashes in a subject suffering therefrom.

Crystalline forms of zuclomiphene citrate

The present invention provides zuclomiphene salts, zuclomiphene binaphthyl hydrogen phosphate salt (1-A)&#xb7;(BPA) and zuclomiphene oxalate salt (1-A)&#xb7;(OXL), crystalline forms thereof and processes for the preparation thereof.

Zuclomiphene salts and crystalline forms thereof

The present invention provides a novel crystalline form of Valbenazine dibesylate, Valbenazine dibesylate Form APO-I, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of hyperkinetic disorders, including tardive dyskinesia.

Crystalline form of Valbenazine dibesylate

There is provided processes for preparing Lapatinib and pharmaceutically acceptable salts thereof by the reductive amination of the aldehyde of Formula II by treatment with 2-methanesulphonylethylamine followed by catalytic hydrogenation in the presence of a suitable hydrogenation catalyst.

Process for the preparation of lapatinib and its ditosylate salt

This invention relates to a process for the preparation of an aminoalkyl phenyl carbamate compound of formula 1, wherein Rand Rindependently are hydrogen or Calkyl; Rand Rare the same or different and each is a lower alkyl; or Rand Rtogether with the nitrogen to which they are attached form a cyclic moiety of a three to eight-member ring, with or without a hetero atom like nitrogen or oxygen; Rand Rindependently are hydrogen, linear, branched or cyclic Calkyl, allyl, propargyl or benzyl; or Rand Rtogether with the nitrogen to which they are attached form a cyclic moiety of three to eight member ring, with or without a hetero atom like nitrogen or oxygen; the carbon center marked with '*' is racemic or enantiomerically enriched (R)- or (S)-configuration; and pharmaceutically acceptable addition salts, and crystalline and amorphous forms thereof comprising the steps of:  

Process for the preparation of phenylcarbamates

The present invention relates to a process for producing 17-N-substituted-carbamoyl-4-aza-androst-1-en-3-ones of formula 1, including Finasteride and Dutasteride.

Process for the preparation of 17-N-substituted-carbamoyl-4-aza-androst-1-en-3-ones

Provided is an efficient method for the preparation of 3-aryloxy-3-arylpropylamines, their optical stereoisomers, and pharmaceutically acceptable salts thereof. The process allows for the isolation of 3-aryloxy-3-arylpropylamines in high yield and purity. The present invention further relates to a process for producing fluoxetine, tomoxetine, norfluoxetine, duloxetine, nisoxetine, and their optically enriched (R)- and (S)-enantiomers.

Growing community of inventors

Brantford, Canada

Mohammed Abdul Raheem